{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 5:', 'Clinical Laboratory Assessments', 'Thrombophilia Screening', 'Protein C deficiency', 'Protein S deficiency', 'Factor V Leiden (genetic testing)', 'Prothrombin mutation (genetic testing)', 'Hepatic Tests', 'Hepatitis C, including:', 'Hepatitis A, including:', 'HCV antibody', 'HAV antibody IgM and IgG', 'HCV RNA PCR - qualitative and quantitative', 'assays', 'Hepatitis B, including:', 'Hepatitis E, including:', 'HBs Ag, anti-HBc antibody, IgM and IgG', 'HEV antibody IgM and IgG', 'Immunogenicity', 'Antidrug Antibodies', 'Note: All assessments will be measured in central laboratory.', 'Abbreviations: ALP=alkaline phosphatase; ALT=alanine transaminase; AST=aspartate transaminase; BUN=blood', 'urea nitrogen; CD4=cluster of differentiation 4; eGFR=estimated glomerular filtration rate; FIX=factor IX;', 'FVIII=factor VIII; GGT= = gamma glutamyl transferase; HAV=hepatitis A virus; HBs Ag=hepatitis B virus surface', 'antigen; HBc=hepatitis B virus core; HCV=hepatitis C virus; HEV=hepatitis E virus; HIV=human', 'immunodeficiency virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; INR=International', 'normalized ratio; MDRD=Modification of Diet in Renal Disease; PCR=polymerase chain reaction; RBC=red', 'blood cell; RNA=ribonucleic acid; WBC=white blood cell.', 'a', 'Will not be communicated to investigational sites.', '7.5.5.1.', 'Additional Laboratory Assessments', 'For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and', 'consultation may be performed for clinical evaluation and/or in consultation with the study', 'Medical Monitor; results may be collected and should be included in the clinical database.', 'Additional laboratory assessments will be performed in patients who experience any LFT', 'abnormalities as outlined in Section 6.2.3.1. Following the occurrence of elevated liver', 'transaminases or other LFT abnormalities per central laboratory, all assessments in Table 6 will', 'be performed one time, as well as hematology, serum chemistry, LFT, and coagulation', 'assessments from Table 5, AT levels, and other assessments or evaluations per Investigator', 'discretion, as appropriate.', 'Monitoring and dose modification will also be performed as outlined in Section 6.2.3.1.', 'Property of the Sanofi Group - strictly confidential', '59']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 6:', 'Hepatic Assessments in Patients who Experience LFT Elevations', 'Extended Hepatic Panel', 'Herpes Simplex Virus 1 and 2 antibody IgM, IgG', 'Herpes Zoster Virus IgM, IgG', 'HIV 1 and 2a', 'HHV-6', 'Cytomegalovirus antibodies, IgM, IgG', 'HBs Ag, HBc antibody IgM and IgG', 'Anti-nuclear antibodies', 'Epstein-Barr Virus antibodies, IgM and IgG', 'Anti-smooth muscle antibodies', 'Anti-mitochondrial antibodies', 'HCV antibody', 'HAV antibody IgM', 'HCV RNA PCR - qualitative and quantitative', 'HEV antibody IgM', 'Imaging', 'Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant', 'Focused Medical and Travel History', 'Use of any potentially hepatotoxic concomitant', 'medications, including over the counter medications', 'and herbal remedies', 'Alcohol consumption', 'Other potentially hepatotoxic agents including any', 'Recent travels to areas where hepatitis A or E is', 'work-related exposures', 'endemic', 'Note: All assessments will be measured in central laboratory. The full panel of assessments should only be performed once;', 'individual assessments may be repeated, as needed.', 'Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBs Ag=hepatitis B', 'virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; HIV=human', 'immunodeficiency virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; MRI=magnetic', 'resonance imagery; PCR=polymerase chain reaction; PT=prothrombin time; RNA=ribonucleic acid', 'a HIV testing will not be performed where prohibited by local regulations.', '7.5.5.2.', 'Immunogenicity', 'Blood samples will be collected to evaluate antidrug antibodies (ADAs) to fitusiran. Blood', 'samples for ADA testing must be collected within 4 hours before IMP administration as', 'specified in the Schedule of Assessments (Table 1). In addition, a blood sample to evaluate', 'ADAs will be collected at the ET visit, if applicable.', 'Details regarding the processing, shipping, and analysis of the samples are provided in the', 'Laboratory Manual.', '7.5.6.', 'Adverse Events', '7.5.6.1.', 'Definitions', 'Adverse Event', 'According to the International Conference on Harmonisation (ICH) E2A guideline Definitions', 'and Standards for Expedited Reporting, and 21 Code of Federal Regulations (CFR) 312.32, IND', 'Safety Reporting, an AE is any untoward medical occurrence in a patient or clinical', 'Property of the Sanofi Group - strictly confidential', '60']\n\n###\n\n", "completion": "END"}